Suven Life Sciences has informed that it enclosed News Release of the company titled 'Suven Life sciences announces Phase 3 Clinical Trial of SUVN-502 (Masupirdine), a 5-HT6 antagonist for treatment of Agitation and aggression in Alzheimer's type dementias'. In compliance with the SEBI (Prohibition of Insider Trading) Regulations, 2015 as amended and in terms of the Code of Conduct of the Company for prevention of Insider Trading, the Trading Window for dealing in the securities of the Company shall remain closed for the Directors, Promoters, other Designated Persons, and immediate relatives of Designated Persons covered under the said code read with the SEBI Regulations, from 17th August 2021 to 18th August 2021. Trading window will be opened from 19th August, 2021.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1652.00 |
| Dr. Reddys Lab | 1235.20 |
| Cipla | 1211.30 |
| Zydus Lifesciences | 923.10 |
| Lupin | 2312.35 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: